Inhibitor regulation of tissue kallikrein activity in the synovial fluid of patients with rheumatoid athritis by Rahman, M. M. et al.
British Journal of Rheumatology 1994;33:215-223
INHIBITOR REGULATION OF TISSUE KALLIKREIN ACTIVITY IN
THE SYNOVIAL FLUID OF PATIENTS WITH RHEUMATOID
ARTHRITIS
M. M. RAHMAN,* K. WORTHY,* C J. ELSON,t E. FINK4 P. A. DIEPPE§ and
K. D. BHOOLA |
Departments of *Pharmacology, fPathology and §Rheumatology, University of Bristol, Bristol;
^Department of Clinical Chemistry and Biochemistry, Surgical City Clinic, University of Munich, Germany
and ^Department of Clinical and Experimental Pharmacology, University of Natal, Durban, South Africa
SUMMARY
Tissue kallikrein (TK) and al-antitrypsin (AT)/TK complexes can be detected in SF from patients with RA if components
of the fluids which interfere with the detection of TK are removed. ot2-Macroglobulin (a2-M) in SF was demonstrated to
contain trapped proteases which were still active in amidase assays. Removal of ct2-M from RA SF reduced their amidase
activity. However, at least some of the remaining activity was due to TK because it was soya bean trypsin inhibitor resistant
and trasylol sensitive and was partly removed by affinity chromatography on anti-TK sepharose. Removal of RF from the
fluids reduced the values obtained for TK levels by ELISA. Addition of SF to human urinary kallikrein (HUK)
considerably reduced the levels of TK detected suggesting the presence of a TK ELISA inhibitor in the fluids. Removal of
components of >300 kDa from SF markedly reduced the TK ELISA inhibitory activity and increased the values for both
the TK and al-AT/TK levels in fluids as measured by ELISA. It is considered this novel inhibitor does not bind to the
active site of TK but rather binds to the site reactive with anti-TK antibodies.
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SEVERAL reports have suggested that pain and swelling
in inflammatory joint disease may be mediated by
kinins formed by the enzymic action of kallikreins
[1-3]. It has been proposed that in the inflamed joint,
inhibitors which regulate the activity of proteases such
as tissue kallikrein (TK) and plasma kallikrein (PK)
may either become ineffective as a result of degra-
dation by oxygen free radicals or be overwhelmed by
an excessive conversion of the kallikrein zymogen into
an active form. One consequence would be the
increased formation of kinins, and another a rise in the
concentration of uninhibited enzymes directly causing
tissue damage. Normal endogenous constraint on the
enzymic activity of tissue kallikrein is exercised by the
serpin inhibitor al-antitrypsin (al-AT), and on plasma
kallikrein by a2-macroglobulin (a2-M) and Cl este-
rase inhibitor. Large quantities of these inhibitors are
present in the SF of patients with RA [4,5], and the
extent to which they control the activity of the two kal-
likreins may be reflected in the degree to which inter-
ferences are observed with assay systems developed to
measure free and uncomplexed TK and PK in SF.
Earlier experiments from this laboratory [6] identi-
fied a TK in SF which was immunoreactive and pos-
sessed enzymic activity both on the synthetic amidase
substrate, D-Val-Leu-Arg-pNA, and on human kinino-
gen, the natural substrate. In order to quantify amidase
activity in body fluids that could be ascribed to TK, it
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was necessary to measure samples in the presence of
soya bean trypsin inhibitor (SBTI), which does not
affect the enzymic activity of TK, but binds to other
enzymes in biological fluids like PK that also hydrolyse
D-Val-Leu-Arg-pNA [7]. Inactive TK can be measured
after activation of samples by thermolysin or by trypsin
(which must itself then be inhibited by SBTI, prior to
the addition of the peptide substrate in the amidase
assay). When we found an inexplicably higher amidase
activity following trypsin activation of SF proenzymes,
we suspected a possible problem on the determination
of precise values for both active and proforms of TK
and PK in such fluids.
Studies of enzyme-inhibitor complexes in RA SF
have indicated the presence of enzymes bound to
either al-AT or a2-M, including PK-a2-M, elastase-
al-AT and al-AT/TK [8-10]. A particular character-
istic of the o2-M molecule is that because of its selec-
tive affinity for trapping PK (88 kDa) and trypsin
(23 kDa) and not TK (35-45 kDa), a2-M constrains
these enzymes without occluding their active site.
Another feature is that once serine proteases become
trapped in the a2-M cleft a diffusion barrier is created
so that inhibitors like SBTI (about 22 kDa) are pre-
vented from gaining access, whereas inhibitors like tra-
sylol (6.5 kDa) gain access readily. However, problems
are created when one attempts to determine precise
values for SBTI-sensitive (PK) and -resistant (TK) in
SF. Because PK is trapped by a2-M, and retains the
capacity to hydrolyse the amidase substrate
(0.58 kDa), spuriously high values would be recorded
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for the SBTI-resistant TK which has no affinity for, and
therefore forms no complexes with cc2-M [4].
The initial aim of this work was thus to determine
whether or not a2-M interfered with TK measure-
ments. Additional studies were directed towards iden-
tifying the activity due to TK in functional assays as
judged by adsorption with solid-phase anti-TK IgG.
Further, attempts to develop an ELISA for the deter-
mination of TK and cd-AT/TK levels in SF, indicated
the presence of substances interfering in these assays.
Therefore, the second aim was to identify the interfer-
ing substances.
PATIENTS AND METHODS
Patients
For these studies two pools of SF were used con-
sisting of fluid collected from the knees of 14 patients
(Table I) with RA treated at the Rheumatology
Department of Bristol Royal Infirmary.
Sample collection
Therapeutically aspirated SF from inflamed joints
was centrifuged at 5000 rpm at room temperature (RT)
for 7 min to remove cells and debris. The supernatants
were thoroughly mixed, aliquoted and stored at -20°C.
Prior to use, the SF were pooled, treated with hyaluro-
nidase (22.5 IU/ml SF for 30 min at 37°C) to reduce vis-
cosity and centrifuged at 5000 rpm for 7 min.
Measurement of TK enzymic activity
1. Amidase assay. The amount of functionally active
TK was measured by assessing the activity of the
enzyme on the synthetic substrate, D-Val-Leu-Arg-
pNA (S2266, Kabivitrum) [11] in the presence of SBTI
as modified by Figueroa et al. [12]. A further develop-
ment of the method allowed measurement of samples
in a microtitre plate (end point assay) rather than in a
spectrophotometer (rate assay), thereby increasing
sensitivity. Briefly, 50 |xl standard human urinary kal-
likrein (12.5-400 ng/ml HUK; Protogen) was added to
100 ul of assay, buffer (0.2 M Tris/Hcl, pH 8.2), or 50 ul
sample was added to 50 ul of buffer containing SBTI
(300 ug) and EDTA (375 ug). The mixtures were incu-
bated at 37°C for 30 min and made up to 150 ul with
buffer. For activation of proenzyme, the sample was
first incubated for 45 min at 37°C with 30 ug trypsin
(Sigma) in a final volume of 100 u,l. Fifty microlitres of
the substrate (S2266) was then added to all samples and
the absorbance at 405 nm measured after a further
incubation for 3 h at 37°C. Non-specific absorbance
due to the samples was determined by incubating the
samples in the absence of the substrate. Assay values
were corrected for the non-specific absorbance. Values
in test samples were calculated by reference to the TK
standard curve and expressed as ng/ml. A standard
curve with an identical concentration range was deter-
mined using the synthetic substrate S2266 in order to
convert the values into mU/mg protein [12].
2. Kininogenase assay. Freeze-dried SF samples were
reconstituted to their original volume with distilled
water, and assayed with kininogen, prepared according
to the method of Marin-Grez and Carretero [13], as the
substrate. A 50 ul sample was incubated with 50 fxl of
kininogen (2 mg/ml in 0.1M NaH2PO4, 3 UM 1, 10-
phenanthroline, 30 UM EDTA, pH 8.5) for 30 min at
37°C. The reaction was terminated with 1 ml 98%
ethanol, and each sample heated to 70°C for 10 min.
The mixture was centrifuged, and the supernatant
transferred to a new micropipete; the precipitate
washed once with 500 uJ of 98% ethanol, centrifuged,
the two supernatants combined and then freeze-dried.
The residue was dissolved in 0.5 ml radioimmunoassay
TABLE I
Clinical details of patients with RA at the time of aspiration (RS)
No.
1
2
3
4
5
6
7
8
9
10
11
12
13
14
Age
(yr)
63
59
48
46
80
61
76
54
54
27
59
71
73
72
Sex
F
M
M
F
F
M
F
F
F
F
F
F
F
F
Joint
RSH
RKN
LKN
RKN
RKN
LKN
RKN
LKN
LKN
LKN
RKN
LKN
RKN
R & L K N
RKN
RKN
LKN
LKN
Duration
(yr)
>10
2-10
<2
2-10
>10
>10
>10
>10
2-10
>10
>10
>10
>10
>10
Pain
Severe
Moderate
Severe
Mild
Mild
Moderate
Severe
Moderate
Severe
Moderate
Severe
None
Mild
Severe
Moderate
Mild
Swelling
+ve
+ve
+ve
+ve
+ve
+ve
+ve
+ve
+ve
+ve
+ve
+ve
+ve
+ve
+ve
+ve
+ve
Volume
(ml)
10
43
8.5
5.5
28
13
20
10
10
37
8
7
18
80
15
90
40
6
Therapy
NSAIDs and 2nd-line
NSAIDs and steroid
NSAIDs and 2nd-line
NSAIDs and 2nd-line
NSAIDs and 2nd-line
NSAIDs and 2nd-line
NSAIDs
NSAIDs
NSAIDs and
steroids
NSAIDs
NSAIDs
NSAIDs and 2nd line
NSAIDs and 2nd line
NSAIDs
Abbreviations: SH, Shoulder, KN, knee.
Second-line drugs: auranofil; azathioprine; gold (i.m.); methotrexate; penicillamine; salazopyrine.
RAHMAN ETAL.: TISSUE KALLIKREIN ACTIVITY IN RA SF 217
(RIA) buffer. The kinin concentration was determined
by RIA [14], and activity expressed as fmole/min/ml of
the original SF volume.
Removal ofo2-M
<x2-M was removed from SF by adsorption with anti-
a2-M IgG (Dakopatts) coupled to CnBr Sepharose. SF
was incubated with an equal volume of anti-oc2-M
Sepharose and 0.2 vol 0.1 M Tris/0.5 M NaCl pH 8.5 for
30 min at room temperature. The mixture was cen-
trifuged and the supernatant collected.
Treatment of samples with solid phase anti-TK
After removal of a2-M, RA SF samples were incu-
bated with 0.1 vol of anti-TK IgG coupled to CnBr
Sepharose in the presence of 0.5 M NaCl and pH 8.5 for
30 min at room temperature. The samples were treated
similarly after activation with trypsin.
Measurement of TK by ELISA
Incubations were for 60 min at 37°C with 100 ul of
solution added to each well of a microtitre plate
(Immulon), unless otherwise indicated. Rabbit anti-
human TK IgG raised by immunizing a rabbit with
purified HUK, (KDB1) [12] (5 ug/ml in carbonate buf-
fer consisting of 15 nw N^COj, 35 DIM NaHCO3, pH
9.6) was used to coat plates. After blocking the plates
(30 min at RT) at first with 5% bovine serum albumin
(BSA) but later with 5% low fat bovine milk (Marvel
original, Premier Brands, UK) in Tris (0.02 M)-NaCl
(0.14 M) 0.05% Tween 20 (Sigma) pH 7.2, the plates
were incubated sequentially at 37°C with: sample or
standard HUK, goat anti-HUK (Protogen: 10 jig/ml),
alkaline-phosphatase-labelled rabbit anti-goat IgG
(Sigma Chemicals; 1:250) and substrate solution
(1 mg/ml p-nitrophenyl phosphate in carbonate buf-
fer). Between each incubation, the wells were rinsed 3x
for 10 sec with excess wash (0.05% Tween 20 in PBS pH
7.4); all reagents were made up, initially in 0.1% BSA/
PBS but later in 5% Marvel. The hydrolysis of sub-
strate was assessed by measuring absorbance at 405 nm
in a Biorad (UK) colorimetric plate reader initially
after 60 min but later 240 min (to increase sensitivity) at
24°C. Non-specific absorbance was determined by per-
forming incubations in the absence of the sample, and
sample values corrected for the non-specific absorb-
ance. For each experiment, values for test samples were
calculated by reference to a simultaneously performed
TK standard curve (range: 20 to 0.01 ng/ml), and
expressed as ng/ml and later as ng/mg protein (as
judged by the Bradford Coomassie blue method). The
minimum detection value for TK in the 240 min incu-
bation experiments was 0.014 ng/ml.
40
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FIG. 1.—Amidase activity of an RA SF pool, before and after incubation of active and activated proenzymes with inhibitors. 1, No inhibi-
tor; 2, soya bean trypsin inhibitor (SBTI); 3, trasylol and SBTI; 4, activated proenzyme with no inhibitor; 5, activated proenzyme with
SBTI; 6, activated proenzyme with trasylol; 7, activated proenzyme with trasylol and SBTI. SBTI inhibits plasma kallikrein and trypsin,
but not tissue kallikrein; whereas trasylol inhibits all three enzymes. The results are the mean and S.D. of three experiments.
218 BRITISH JOURNAL OF RHEUMATOLOGY VOL. 33 NO. 3
FIG. 2.—Double immunodiffusion against anti-a2-M, showing
the presence of a2-M in SF, and its absence after filtration
through 300 kDa filter. 1, RA SF; 2, RA SF absorbed IgG sepha-
rose; 3, fraction of RA SF retarded by 300 kDa filter; 4, RA SF
centrifuged through 300 kDa filter; 5, saline.
al-AT/TK ELISA
al-AT/TK complexes were prepared by incubating
25 ul of 0.8 ng/ml of lyophilized HUK (Green Cross
Corporation, Osaka, Japan) with 25 ul of 100 ug/ml of
al-antitrypsin (Sigma Chemicals, UK). Both reagents
were diluted in 0.2 M Tris-HCl buffer (pH 8.2). For the
complex ELISA, the Immulon microtitre plate was
coated with the polyclonal rabbit anti-TK IgG
(KDB1), diluted in coating buffer (see TK ELISA) to
give a concentration of 5 ug/ml. Next, the microtitre
plate was incubated for 30 min at room temperature,
with 5% Marvel to block the unoccupied sites. Sub-
sequently, the plate was incubated either with test
sample or with al-AT/TK complexes to generate
curves with concentrations of complexes that ranged
from 0.05 to 50 ng/ml. At the end of this period sheep
antihuman al-AT conjugated with alkaline phospha-
tase (Serotec, UK) was added in a dilution of 1.250.
Finally, the well contents were incubated (overnight)
with the substrate (disodium p-nitrophenol phosphate,
1 mg/ml) for the alkaline phosphatase to develop the
chromophore. The absorbance values were read on the
Biorad plate reader. For each step, unless otherwise
stated, the plate was incubated for 1 h at 37°C and
washed three times (for 10-sec periods) between steps
with PBS-Tween 20 buffer (pH 7.4). Values for test
samples were calculated from the standard curve gen-
erated for each experiment, and expressed as
al-AT/TK ng/mg protein.
A second al-AT/TK-complex ELISA was devel-
oped using biotin-extravidin conjugates. After apply-
ing the primary antibody (KDB1), samples and the
second antibody (sheep anti-human al-AT, 8 ug/ml),
biotin conjugated anti-sheep IgG (1.2000) was added,
and thereafter extravadin labelled alkaline phospha-
tase. All further steps were performed as already
described except that the incubation time with the sub-
strate was 2 h. Overall these modifications increased
the sensitivity of detection fourfold.
Removal of high molecular weight components from SF
SF were filtered through 300 kDa filtration mem-
branes (Ultrafree, Millipore, Japan) by centrifugation
at 5000 rpm at 4°C for 12 h.
Removal of RF from SF
SF, either pooled or individual samples, were incu-
bated with 0.3 vol of heat aggregated rabbit IgG
coupled to CnBr Sepharose and 0.2 vol of 0.1 M Tris/0.5
M NaCl pH 8.5 for 30 min at room temperature. Remo-
val of RF was verified by assaying for the presence
human IgM bound to IgG coated microtitre plates. In
addition, TK standards (0.63,2.5,10 ng/ml HUK) were
measured in the presence of SF following adsorption of
RF.
Spiking experiments
Known amounts of RA SF were added to varying
concentrations of HUK and TK measured.
Attempts to remove or destroy TK inhibitors in SF
The treatments included: (a) pre-incubation with
5 mg of SBTI/ml for 30 min at 37°C, (b) acid-heat treat-
ment: acidification with HC1 to pH 4.0 for 30 min at
room temperature, followed by heating at pH 7.0 at
60°C for 45 min, (c) centrifugation through membranes
with either 10, 100 or 300 kDa cut off (Ultrafree,
Millipore).
RESULTS
The initial experiments which alerted us to a possible
problem with a2-M are shown in Fig. 1. They were
designed to determine the amidase activity profile of an
RA SF pool. Note particularly the high amidase activ-
ity of SF after trypsin activation of precursor enzymes
(column 4) which was only partly inhibited by SBTI
(column 5) but reduced substantially by trasylol
(column 6). Since SBTI inhibits only PK and trypsin
but not TK whereas trasylol inhibits all three enzymes
these results could indicate that there are large
amounts particularly of precursor TK in RA SF. On the
other hand, as trasylol has access to a2-M trapped pro-
teases while SBTI has no access, they could suggest that
trypsin and other enzymes were bound by a2-M and
were still available to cleave the amidase substrate.
To distinguish between these possibilities experi-
ments were set up to determine the effect of removing
a2-M amidase activity in RA SF. The first approach to
remove a2-M was by centrifugation through millipore
filters with an exclusion value of 300 kDa. The efficacy
of this procedure was confirmed by Ouchterlony gel
diffusion (Fig. 2). The amidase activity in the retarded
and filtered fractions of an RA SF pool is shown in
Figs 3(a) and 3(b). It can be seen that the amounts of
active and proenzyme in the filtered fraction were con-
siderably reduced as compared with the retarded frac-
tion. Comparison of the amidase activity in the filtered
RAHMAN ETAL.: TISSUE KALLIKREIN ACnVITY IN RA SF 219
0.20
18
16 -
14 -
1"
I
10 -
8 -
6 -
4 -
2 -
(a)
Active enzyme Pro-enzyme
1 2 3 4 5 6 7
FIG. 3.—Amidase activity of (a) the retarded and (b) filtered fractions of RA SF, after centrifugation through 300 kDa millipore filters.
The protein concentration of the samples was; 45.1 mg/ml for untreated RA SF; 31.67 mg/ml for fraction of RA SF retarded by 300 kDa
millipore filter; and 9.04 mg/ml for fraction filtered through 300 kDa millipore filter. For the inhibitor profiles consult Fig. 1. The results
are the mean and S.D. of three experiments.
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TABLE II
Effect of removing ot-2 macroglobulin on RA SF amidase and
kininogenase activity
Amidase
(mU/ml)
Plus a2-macroglobulin
SF
SF + SBTI
SF + tryp-
sin + SBTI
57.00
6.40
254.00
Minus a2-macroglobulin
SF
SF + SBTI
SF + Tryp-
sin + SBTI
12.90
0.72
4.25
%
100.00
5.60
445.00
22.60
1.26
7.40
Kininogenase
(fmole/ml)
101.00
3.00
708.00
53.00
3.00
13.00
%
100.00
2.90
700.00
52.40
2.93
12.80
Abbreviation: SBTI, soya bean trypsin inhibitor.
0.08
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0.63 1.25 2.5 5 10 20
Concentration (ng/ml)
FIG. 4(a).—Effect of removing RF from an RA SF pool on the
measurement of TK by ELISA. 1, Untreated SF; 2, elute from
IgG Sepharose; 3, fraction of RA SF retarded by 300 kDa milli-
pore filter, 4, fraction of RA SF filtered through 300 kDa milli-
pore filter. The results are the mean and S.D. of three
experiments, (b) Inhibitory effect of RF absorbed (IgG Sepha-
rose) RA SF pool on the measurement of a tissue kallikrein
(HUK) standard curve by ELJSA. Continuous line, HUK stan-
dard curve. , HUK standard curve in the presence of neat RF
factor absorbed SF. The results are the mean and S.D. of three
experiments.
fractions following incubation with the inhibitors,
SBTI (inhibits PK) and trasylol (inhibits both kallik-
reins), provided true estimates of the relative propor-
tions of both active and pro tissue and PK in RA SF.
In the second approach, a SF pool from RA patients
was preadsorbed with solid-phase anti-a2-M. The suc-
cessful removal of immunoreactive a2-M from the
fluid was verified by Ouchterlony immunoprecipitation
and Western blotting (results not shown). In these
experiments the amidase and kininogenase activities in
the pool were compared, before and after removal of
ce2-M (Table II). The results showed that the SBTI-
resistant activity was reduced by removal of a2-M
(which contained the o2-M trapped proteases),
whereas the kininogenase activity was not affected.
Prokallikreins (tissue and plasma) in SF treated with
trypsin and converted into their respective active forms
resulted in high activities, both of which were reduced
after the removal of ct2-M.
In order to verify the presence of TK in a2-M
depleted RA SF, the amidase activity was measured
before and after adsorption with anti-TK IgG. Addi-
tionally, the amount of tissue prokallikrein (following
trypsin activation) was measured similarly after
adsorption with anti-TK IgG. The results showed that
solid phase anti-TK removed 25% (n = 3) of active and
31% (n = 6) of pro enzyme TK.
Immunoreactivity of TK in'SF
Experiments were designed to determine the levels
of immunoreactive TK in SF by ELISA. As RF (mainly
IgM anti-IgG) is known to interfere with such immu-
noassays, the effect of removing RF on the ELISA
measurements of TK was examined. Removal of the
RF from pooled SF reduced the apparent TK value
0
FIG. 5.—Effect of various treatments on the ability of RF
absorbed RA SF to inhibit the measurement of TK by ELISA. 1,
None; 2, addition of soya bean trypsin inhibitor (SBTI); 3, acid/
heat; 4, removal of <10 kDa components; 5, removal of ct2-M; 6,
removal of >100 kDa components; 7, removal of >300 kDa
components.
RAHMAN ETAL.: TISSUE KALLIKREIN ACTIVITY IN RA SF 221
^-y 2
I
o
1.8
1.6
x
a
8
a. 1.4
1.2
5 0.8
"2 0.6
3 0.4
"a
§ 0.2
^ 0
T
I
2 3 4 5
FIG. 6.—Measurement of al-AT/TK complexes by ELISA. 1,
RA SF pool; 2, RF absorbed (IgG Sepharose) SF; 3, Sepharose
absorbed SF; 4, fraction of SF retarded by 300 kDa millipore fil-
ter; 5, fraction of SF filtered through 300 kDa millipore filter.
The results are the mean and S.D. deviation of three experiments.
when measured by ELISA [Fig. 4(a)]. The question as
to whether the new basal value represented a true level
of TK in SF was addressed next. Accordingly, RF-
adsorbed SF was added to the HUK standard curve
and remeasured. It can be seen from Fig. 4(b) that
there was a marked inhibition of the TK standard curve
in the presence of SF.
Studies on inhibitors in RA SF
The ELISA results suggested that an inhibitor might
be present in RA SF. To examine this possibility, a RF-
adsorbed SF pool was treated in several ways, and the
effect of these treatment on the recovery of added TK
was determined. As illustrated in Fig. 5, only about 6%
was recovered when TK was added to the untreated
pool or that in which protease activity had been
inhibited by SBTI or acid/heat treatment. Removal of
components of less than 10 kDa or removal of a2-M
failed to improve recovery substantially. By contrast, if
SF components greater than 100 kDa or 300 kDa were
removed prior to spiking, there was a considerable
improvement of recovery.
One possibility was that TK had become complexed
to cd-AT. We therefore examined RA SF for the pres-
ence of al-AT/TK complexes. Fig. 6 shows that such
complexes can be detected in RA SF. Whereas removal
of RF reduced the values, filtration through 300 kDa
exclusion membrane resulted in a fourfold increase in
the specific activity of the al-AT/TK complexes.
Similar results were obtained with individual RA SF
(results not shown).
Comparison ofTK functional activity and immunoreac-
tivity in SF
In order to determine whether the inhibition
observed in the ELISA experiments affected the func-
tional activity of TK we compared in both assays recov-
ery of TK added to SF. Whereas in the TK ELISA, the
markedly reduced recovery of added TK was seen with
both untreated and a2M-free SF, this was not the case
when similar experiments were performed to examine
the functional activity of the enzyme in the amidase
assay as shown in Fig. 7.
DISCUSSION
The first question asked in this paper is whether
a2-M interferes with the measurement of active TK in
RA SF. The results show that the SF amidase activity of
both active and precursor enzyme was inhibited to a
greater degree by trasylol which has access to a2-M
trapped proteases than by SBTI which has no access.
Similarly, the removal of a2-M by filtration or affinity
chromatography substantially reduced the SF amidase
activity. Thus much of the SBTI-resistant amidase
activity in RA SF is due to a2-M protected proteases.
It may be asked which enzyme(s) is responsible for
the activity on the S2266 substrate remaining after
removal of a2-M. The results suggest that it is due to
the presence of both PK and TK. The remaining activ-
ity was reduced by SBTI. As SBTI inhibits PK but not
TK then the SBTI inhibitable activity is likely to be due
to PK. Trasylol (inhibits both enzymes) reduced the
remaining activity further which is consistent with the
trasylol sensitive but SBTI resistant activity being
attributable to TK. In support of this contention some
25% of the amidase activity of a2-M depleted RA SF
was removed by affinity chromatography on solid
a 100
g
75
T3
I
o
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Amidase activity Immunoreactivity
FIG. 7.—Comparison between effects of RA SF on measurement
of TK by amidase and ELISA assay. 1, Untreated RA SF; 2,
removal of a2-M; 3, fraction of RA SF filtered through 100 kDa
millipore filter; 4, untreated RA SF; 5, removal of ot2-M by affin-
ity chromatography; 6, fraction of RA SF filtered through
100 kDa millipore filter; 7, fraction of RA SF filtered through
300 kDa millipore filter, The results are the mean and S.D. of
three experiments.
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phase anti-TK. Since (see below) RA SF contains a fac-
tor which interferes which anti-TK binding to TK, then
the amount of TK removed from RA SF by solid phase
anti-TK is probably an underestimate. It is clear there-
fore that at least some active and proenzyme TK is
present in RA SF. Moreover, these results show that
the removal of oc2-M from any body fluid containing
this inhibitor is essential before attempting to measure
functional TK in such fluids.
The addition of RF absorbed RA SF to HUK inter-
fered profoundly with the measurement of this TK by
ELISA. It follows that the fluids contain some form of
inhibitor. Attempts were made to gain further infor-
mation about the nature of this inhibitor. One possi-
bility is that the added HUK could be destroyed by
proteases present in the SF. The fact that recovery was
not improved by SBTI- or acid-heat treatment of SF
militates against this hypothesis. The possibility that
TK ELISA inhibition was due to the pH or ionic
strength of SF was excluded by the fact that removal of
low molecular weight components from SF did not
abrogate the inhibitory effect. However, removal of
components greater than 300 kDa MW was associated
with loss of ELISA inhibitory activity on added TK.
Additionally, the fact that higher values for immuno-
reactive TK were measured in SF passed through
300 kDa filters than in RF absorbed SF [cf columns 2
and 4, Fig. 4(a)] suggests that removal of the high mol-
ecular weight inhibitor enables TK to be detected by
ELISA in RA SF and thereby provides further support
for the conclusion already attained that TK is present
in such fluids.
In other experiments al-AT/TK complexes were
detected by ELISA in RA SF albeit at low levels. How-
ever, removal of components of greater than 300 kDa
sharply increased the values obtained. This result sug-
gests that the same ELISA inhibitor interferes with the
detection of al-AT/TK complexes. The question arises
as to how the inhibitor interferes with the detection of
TK. The fact that TK added to SF was more easily
detected by the amidase assay than by ELISA suggests
that the active site of TK is not blocked. It follows that
the substance in RA SF interfering with the TK ELISA
could be non-specific or due to an inhibitor which binds
to a non-enzymic site on TK and thereby interferes
with the access of anti-TK to TK. In support of the
latter contention an inhibitor with the same properties
has been found in normal human sera [10] and in the
supernatants from degranulated neutrophils (unpub-
lished results) but not urine or saliva [10] and RA SF
does not interfere with the detection of PK by ELISA
(unpublished results).
It is now clear that neutrophils stimulated by soluble
IgG aggregates release their granule enzymes into the
SF of RA patients [15, 16]. Work from our laboratory
[13] has also revealed the presence of TK within the
granules of the human neutrophil, and of kininogen
substrates on the surface of the same cell [17, 18]. It is
therefore possible that TK may act to release kinins
locally on the neutrophil surface rather than in the
general synovial compartment. This mechanism may
provide for a more subtle control mechanism for kinin
production within the inflamed joint. Work is in pro-
gress to establish whether TK released from granules is
bound to be neutrophil surface and whether the kinin
moiety is missing from RA synovial PMNs.
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